18 patents
Utility
Methods of Treating Neutorpenia Using G-CSF Protein Complex
19 Oct 23
This disclosure provides a method of preventing, alleviating or treating a condition (i.e., neutropenia) in a subject in need thereof, the condition characterized by compromised white blood cell production in the subject.
Gajanan Bhat, Shanta Chawla, Jae Hyuk Choi, Eun jung Kim, Yu Yon Kim, Gyu Hyan Lee, Hyesun Han
Filed: 16 May 23
Utility
Methods for Promoting Anti-tumor Immune Response In a Subject In Need Thereof Using Encapsulated Interleukin 12
7 Sep 23
The present invention relates to methods for promoting anti-tumor immune response in a subject in need thereof using encapsulated interleukin 12 (IL-12).
Sribalaji Lakshmikanthan, Prasad Kolli, Francois Lebel, John A. Barrett
Filed: 3 Mar 23
Utility
Novel Methods of Treating Neutorpenia Using G-CSF Protein Complex
31 Aug 23
This disclosure provides a method of preventing, alleviating or treating a condition (i.e., neutropenia) in a subject in need thereof, the condition characterized by compromised white blood cell production in the subject.
Gajanan Bhat, Shanta Chawla, Jae Hyuk Choi, Eun jung Kim, Yu Yon Kim, Gyu Hyan Lee, Hyesun Han
Filed: 10 Mar 23
Utility
Methods of treating neutorpenia using G-CSF protein complex
27 Jun 23
This disclosure provides a method of preventing, alleviating or treating a condition (i.e., neutropenia) in a subject in need thereof, the condition characterized by compromised white blood cell production in the subject.
Gajanan Bhat, Shanta Chawla, Jae Hyuk Choi, Eun Jung Kim, Yu Yon Kim, Gyu Hyan Lee, Hyesun Han
Filed: 18 Aug 20
Utility
Inhibitors of Mutant Family Tyrosine-kinases
6 Apr 23
An epidermal growth factor receptor (EGFR) family tyrosine kinase inhibitor comprising a functional group that can bind to the serine S797 residue in EGFR having a C797S mutation or the serine S805 residue in HER2 having a C805S mutation.
Prasad V. Chaturvedula, Prasad Kolli
Filed: 21 Nov 22
Utility
Methods of Treatment Using G-CSF Protein Complex
26 Jan 23
This disclosure provides a method of preventing, alleviating or treating a condition (i.e., neutropenia) in a subject in need thereof, the condition characterized by compromised white blood cell production in the subject.
Shanta Chawla, Gajanan Bhat
Filed: 4 Dec 20
Utility
Ready-to-use formulation for Vincristine Sulfate Liposome Injection
24 Jan 23
Disclosed herein are various compositions comprising neoplastic formulations and their methods of use.
William T. Monte, Robert Malcolm Abra, Bing Luo, Yuanpeng Zhang
Filed: 22 Jul 16
Utility
Compositions comprising disodium levofolinate
3 Jan 23
Provided herein are compositions comprising disodium levofolinate.
Ramsharan Singh, Bahman Shimiaei
Filed: 25 Jan 19
Utility
Poziotinib Combination with VEGFR2 Inhibitors and Methods of Use Thereof
22 Sep 22
A drug combination containing poziotinib or a pharmaceutically acceptable salt thereof and a VEGFR2 inhibitor and methods of using the combination for treating cancer in a subject in need thereof.
Guru Reddy
Filed: 21 Aug 20
Utility
Combination therapy using belinostat and pralatrexate to treat lymphoma
13 Sep 22
The present invention relates to compositions and methods for treating lymphoma in a subject in need thereof, said methods comprising administering to the patient in need thereof a therapeutically effective amount of a combination of belinostat and pralatrexate, wherein said therapeutically effective amount results in a synergistic antiproliferative effect on cancer cell growth.
Guru Reddy
Filed: 14 Jun 16
Utility
Methods of treatment using G-CSF protein complex
8 Mar 22
This disclosure provides a method of preventing, alleviating, or treating a condition (i.e., neutropenia) in a patient in need thereof, the condition characterized by compromised white blood cell production in the patient.
Gajanan Bhat, Shanta Chawla
Filed: 31 May 19
Utility
Kits and Methods for Treating Cancers
10 Feb 22
A kit containing a crystalline form of a quinazoline compound.
Guru Reddy
Filed: 12 Sep 19
Utility
Methods of Treating Chemotherapy Induced Neutropenia Using Fixed Doses of G-CSF Protein Complex
20 Jan 22
This disclosure provides a method of preventing, alleviating, or treating a condition (i.e., neutropenia) in a patient in need thereof, the condition characterized by compromised white blood cell production in the patient.
John A. Barrett, Sribalaji Lakshmikanthan
Filed: 13 Jul 21
Utility
Novel Quinazoline Egfr Inhibitors
18 Nov 21
This document discloses a novel class of quinazoline EGFR inhibitors.
Prasad V. Chaturvedula
Filed: 20 Sep 19
Utility
Poziotinib Combinations with an ANTI-HER1, HER2 or HER4 Antibody and Methods of Use Thereof
26 Aug 21
Provided are combinations of poziotinib and an anti-HER1, anti-HER2 or anti-HER4 antibody, optionally with other agents, and use of the combinations for treating cancer.
Guru Reddy, Sunyoung Jang, Jooyun Byun
Filed: 25 Jun 19
Utility
Combination of Poziotinib with Cytotoxic Agent And/or Other Molecularly Targeted Agent and Use Thereof
20 May 21
Provided are a combination of poziotinib and at least one agent selected from the group consisting of cytotoxic agents and molecularly targeted agents; and a use of the combination.
Guru Reddy
Filed: 25 Jun 19
Utility
Novel Methods of Treating Neutorpenia Using G-CSF Protein Complex
14 Jan 21
This disclosure provides a method of preventing, alleviating or treating a condition (i.e., neutropenia) in a subject in need thereof, the condition characterized by compromised white blood cell production in the subject.
Gajanan Bhat, Lee Allen, Jae Hyuk Choi, Eun Jung Kim, Yu Yon Kim, Gyu Hyan Lee, Hyesun Han
Filed: 18 Aug 20
Utility
Inhibitors of Mutant Family Tyrosine-kinases
19 Aug 20
An epidermal growth factor receptor (EGFR) family tyrosine kinase inhibitor comprising a functional group that can bind to the serine S797 residue in EGFR having a C797S mutation or the serine S805 residue in HER2 having a C805S mutation.
Prasad V. Chaturvedual, Prasad Kolli
Filed: 17 Oct 18
- Prev
- 1
- Next
Patents are sorted by USPTO publication date, most recent first